Rapamycin Ameliorates Experimental Autoimmune Encephalomyelitis by Suppressing the mTOR-STAT3 Pathway

[1]  A. Ghaemi,et al.  Rapamycin Augments Immunomodulatory Properties of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Encephalomyelitis , 2016, Molecular Neurobiology.

[2]  Li Guo,et al.  Metformin ameliorates the development of experimental autoimmune encephalomyelitis by regulating T helper 17 and regulatory T cells in mice , 2016, Journal of Neuroimmunology.

[3]  F. Rueda,et al.  Interleukin‐17‐ and interleukin‐22‐secreting myelin‐specific CD4+ T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients , 2016, Immunology.

[4]  B. Tong,et al.  Arctigenin exerts anti-colitis efficacy through inhibiting the differentiation of Th1 and Th17 cells via an mTORC1-dependent pathway. , 2015, Biochemical pharmacology.

[5]  Jing Zhang,et al.  Tripchlorolide ameliorates experimental autoimmune encephalomyelitis by down‐regulating ERK1/2‐NF‐κB and JAK/STAT signaling pathways , 2015, Journal of neurochemistry.

[6]  B. Baradaran,et al.  The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels. , 2015, Immunology letters.

[7]  Wenwei Liu,et al.  Kirenol Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Differentiation of Th1 and Th17 Cells and Inducing Apoptosis of Effector T Cells , 2015, Scientific Reports.

[8]  Weizhen Zhang,et al.  Ghrelin Inhibits the Differentiation of T Helper 17 Cells through mTOR/STAT3 Signaling Pathway , 2015, PloS one.

[9]  Wenjing Deng,et al.  A natural flavonoid glucoside icariin inhibits Th1 and Th17 cell differentiation and ameliorates experimental autoimmune encephalomyelitis. , 2015, International immunopharmacology.

[10]  Qiang Sun,et al.  Decreased expression of IL-27 and its correlation with Th1 and Th17 cells in progressive multiple sclerosis , 2015, Journal of the Neurological Sciences.

[11]  T. Rauen,et al.  CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance. , 2014, The Journal of clinical investigation.

[12]  Shu Han,et al.  An ανβ3 Integrin-Binding Peptide Ameliorates Symptoms of Chronic Progressive Experimental Autoimmune Encephalomyelitis by Alleviating Neuroinflammatory Responses in Mice , 2014, Journal of Neuroimmune Pharmacology.

[13]  W. Cui,et al.  MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis , 2014, Journal of Neuroimmunology.

[14]  Ying Wang,et al.  Sulforaphane ameliorates the development of experimental autoimmune encephalomyelitis by antagonizing oxidative stress and Th17-related inflammation in mice , 2013, Experimental Neurology.

[15]  D. Feinstein,et al.  mTOR kinase, a key player in the regulation of glial functions: Relevance for the therapy of multiple sclerosis , 2013, Glia.

[16]  H. Nam,et al.  Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma , 2013, Clinical & Experimental Metastasis.

[17]  Y. Wan,et al.  Dihydroartemisinin Ameliorates Inflammatory Disease by Its Reciprocal Effects on Th and Regulatory T Cell Function via Modulating the Mammalian Target of Rapamycin Pathway , 2012, The Journal of Immunology.

[18]  D. Feinstein,et al.  Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis , 2012, Journal of Neuroimmunology.

[19]  Yang Liu,et al.  Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice. , 2010, The Journal of clinical investigation.

[20]  Hongbo Chi,et al.  S1P1-mTOR axis directs the reciprocal differentiation of TH1 and regulatory T cells , 2010, Nature Immunology.

[21]  J. O’Shea,et al.  Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. , 2010, Immunity.

[22]  M. Lynch,et al.  Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis , 2010, Brain, Behavior, and Immunity.

[23]  G. Martino,et al.  Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation , 2010, Journal of Neuroimmunology.

[24]  S. Fournier,et al.  Characterization of relapsing–remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice , 2009, Glia.

[25]  M. Donia,et al.  Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. , 2009, Journal of autoimmunity.

[26]  P. Worley,et al.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. , 2009, Immunity.

[27]  J. Russell,et al.  Regional CNS responses to IFN-γ determine lesion localization patterns during EAE pathogenesis , 2008, The Journal of experimental medicine.

[28]  J. Margolick,et al.  Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance , 2007, Proceedings of the National Academy of Sciences.

[29]  H. Hartung,et al.  Immunosuppressive agents in multiple sclerosis , 2007, Neurotherapeutics.

[30]  Y. Kondo,et al.  Roles of mTOR and STAT3 in Autophagy Induced by Telomere 3' Overhang-Specific DNA Oligonucleotides , 2007, Autophagy.

[31]  M. Kamoun,et al.  Induction of Experimental Autoimmune Encephalomyelitis in IL-12 Receptor-β2-Deficient Mice: IL-12 Responsiveness Is Not Required in the Pathogenesis of Inflammatory Demyelination in the Central Nervous System1 , 2003, The Journal of Immunology.

[32]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[33]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[34]  Richard A. Rudick,et al.  Quantification of Self-Recognition in Multiple Sclerosis by Single-Cell Analysis of Cytokine Production1 , 2000, The Journal of Immunology.

[35]  Laurie H Glimcher,et al.  A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment , 2000, Cell.

[36]  P. Lebon,et al.  Interferon-γ and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions , 1988, Journal of the Neurological Sciences.

[37]  Li Guo,et al.  Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice. , 2016, International immunopharmacology.

[38]  G. Becker,et al.  Role of the phosphatidylinositol 3-kinase and mTOR pathways in the regulation of renal fibroblast function and differentiation. , 2007, The international journal of biochemistry & cell biology.

[39]  J. Avruch,et al.  Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR , 2000, Current Biology.

[40]  P. Lebon,et al.  Interferon-gamma and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions. , 1988, Journal of the neurological sciences.